How can I improve the renal function (eGFR ~40 mL/min/1.73 m², elevated urea and creatinine) in a 65‑year‑old patient with mild heart failure, recent NSAID overuse, diabetes on dapagliflozin 10 mg daily, who has stopped telmisartan (ARB) and hydrochlorothiazide, and is now taking sildenafil 20 mg, spironolactone, and furosemide half dose on alternate days?

Management Strategy for Improving Renal Function in This Patient

Continue dapagliflozin 10 mg daily and maintain current diuretic regimen while closely monitoring renal function, as the NSAID-induced component is likely reversible and SGLT2 inhibitors provide renoprotective benefits even at this eGFR level. 1, 2

Rationale for Current Approach

NSAID Discontinuation: The Critical First Step

The recent NSAID overuse is the most likely reversible cause of the acute-on-chronic kidney dysfunction 3. NSAIDs cause:

• Afferent arteriolar vasoconstriction reducing glomerular perfusion
• Direct tubular toxicity
• Interference with compensatory prostaglandin-mediated vasodilation

With NSAID cessation, expect gradual improvement over 2-4 weeks. Monitor creatinine weekly initially 3.

Dapagliflozin: Continue Despite eGFR of 40

The decision to continue dapagliflozin is strongly supported by recent evidence:

• FDA labeling permits continuation down to eGFR 25 mL/min/1.73 m² for heart failure and renal protection indications 2
• DAPA-CKD trial demonstrated 44% reduction in renal outcomes (sustained eGFR decline ≥50%, ESKD, or renal/CV death) in patients with eGFR 25-75 1
• EMPEROR-Reduced showed slower annual eGFR decline with empagliflozin (0.55 vs 2.28 mL/min/1.73 m²/year) 1
• Patients experiencing eGFR deterioration to <25 still benefited from continuation (HR 0.53 for primary outcomes) 4

Common pitfall: An "initial dip" in eGFR of 5-10 mL/min within 2 weeks of SGLT2 inhibitor initiation is expected and represents hemodynamic adjustment (reduced intraglomerular pressure), not tubular injury 5, 6. This is actually protective long-term. Do not discontinue for this reason alone.

Stopping Telmisartan: Reassess This Decision

This requires careful reconsideration. While stopping the ARB may have been appropriate acutely with NSAID toxicity, guidelines support reintroduction once stable 3:

• In stable heart failure with creatinine <250 μmol/L (~2.8 mg/dL), ACE inhibitors/ARBs should be continued 3
• Current creatinine of 1.44 mg/dL (~127 μmol/L) is well below this threshold
• ARBs reduce mortality and morbidity in heart failure 7

Recommendation: Once renal function stabilizes (2-3 weeks post-NSAID cessation), cautiously reintroduce telmisartan at low dose (20-40 mg daily), monitoring potassium and creatinine at 1 week, then 2 weeks 3.

Stopping Hydrochlorothiazide: Appropriate

This was the correct decision 8:

• Thiazides are ineffective when eGFR <30 mL/min except when combined synergistically with loop diuretics
• At eGFR 40, thiazides have minimal diuretic efficacy
• Risk of hyponatremia and electrolyte disturbances outweighs benefits

Diuretic Management Strategy

Current Regimen Assessment

Spironolactone plus furosemide half-dose on alternate days is suboptimal for several reasons:

Better approach 3, 7:

• Daily low-dose furosemide (20-40 mg once daily) is superior to alternate-day dosing for maintaining euvolemia
• Spironolactone 12.5-25 mg daily (not alternate days) provides consistent aldosterone blockade
• The 100:40 spironolactone:furosemide ratio maintains normokalemia 9

Monitor closely:

• Potassium every 5-7 days initially, then weekly until stable 8
• If potassium >5.5 mEq/L, reduce spironolactone dose or frequency
• If volume overload persists, increase furosemide to twice daily rather than increasing single dose 3

Mineralocorticoid Receptor Antagonist Continuation

Spironolactone should be continued despite eGFR 40 10:

• RALES/EMPHASIS-HF pooled analysis showed benefit persists even when eGFR declines to <30 mL/min/1.73 m²
• Risk reduction for CV death/HF hospitalization: HR 0.65 (95% CI 0.43-0.99) in those with eGFR <30
• Absolute risk reduction of 21 events per 100 person-years outweighs 3 excess severe hyperkalemia events 10

Caveat: With diabetes and eGFR 40, hyperkalemia risk is elevated. Start/maintain at 12.5 mg daily with frequent monitoring 11.

Monitoring Protocol

Week 1-2 (Acute Phase Post-NSAID)

• Creatinine, BUN, electrolytes: twice weekly
• Daily weights
• Assess volume status clinically
• Watch for "initial dip" with dapagliflozin (expected, benign) 5, 12

Week 3-4 (Stabilization Phase)

• Creatinine, electrolytes: weekly
• If stable, consider reintroducing low-dose ARB
• Adjust diuretics based on volume status

Month 2-3 (Maintenance Phase)

• Creatinine, electrolytes: every 2 weeks, then monthly
• Expect gradual eGFR improvement as NSAID effect resolves
• Target: eGFR stabilization or improvement to 45-50 range

Expected Trajectory

Realistic expectations:

• Weeks 1-2: Possible further small eGFR decline (initial dip from dapagliflozin)
• Weeks 2-4: Stabilization as NSAID effect resolves
• Months 2-3: Gradual improvement, potentially 5-10 mL/min recovery
• Long-term: Slower eGFR decline rate with dapagliflozin (0.55 vs 2.28 mL/min/year) 1

Red Flags Requiring Intervention

Stop or reduce medications if:

• Creatinine rises >50% from baseline despite NSAID cessation 3
• Potassium >6.0 mEq/L on two consecutive measurements 10
• Symptomatic hypotension (MAP <65 mmHg)
• Oliguria (<400 mL/day) with rising creatinine 3

These suggest true tubular injury rather than hemodynamic changes and require reassessment 5, 6.

Additional Considerations

Sildenafil 20 mg

This dose suggests treatment for pulmonary hypertension rather than erectile dysfunction. Continue as prescribed; no significant renal effects expected.

Diabetes Management

Dapagliflozin provides dual benefit for diabetes and cardio-renal protection. No additional glucose-lowering agents mentioned—ensure adequate glycemic control without hypoglycemia risk.

Volume Status

With "mild heart failure" and normal BP, patient appears euvolemic. Avoid aggressive diuresis that could worsen renal function 3. The goal is gentle decongestion, not dehydration.